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We present capillary electrophoresis-mass spectrometry (CE-MS) in combination with 
advanced chemometric tools for the analysis of bioactive compounds in food, in 
particular for the identification of antihypertensive peptides in a nutraceutical derived 
from a bovine milk protein hydrolysate. Different extracts of the nutraceutical were 
analyzed by CE-MS, and the electropherograms were processed using a novel data 
analysis workflow that included regions of interest (ROIs) compression and multivariate 
curve resolution alternating least squares (MCR-ALS). MCR-ALS permitted the 
description of the nutraceutical extract as ten characteristic components with their 
electrophoretic profiles and mass spectra. Twenty-two compounds were tentatively 
identified as antihypertensive bovine casein fragments through a mass search in a 
database of bioactive peptides. The identity of 17 antihypertensive peptides was reliably 
confirmed by capillary electrophoresis-tandem mass spectrometry. The proposed 
analytical approach demonstrated the potential to obtain a characteristic and activity-






Many peptide fragments derived from food protein hydrolysates are of great interest in 
food and pharmaceutical sciences because they present different physiological roles, 
providing benefits in human health [1–6]. Milk and milk-derived protein hydrolysates 
are one of the most studied sources of biologically active peptides and they are regarded 
as potential ingredients of functional dairy foods, nutraceuticals, and cosmetics [1–3]. 
Bovine milk is accessible and inexpensive and contains approximately 3.5% (m/m) of 
proteins, with 80% (m/m) of casein (CSN) and 20% (m/m) of whey proteins [1]. Many 
bovine CSN and whey protein fragments with different bioactivities have been 
described, including, among others, immunostimulation, antimicrobial, opioid, metal 
binding, antithrombotic, allergenic and angiotensin converting enzyme (ACE) inhibition 
[1–3,7–9]. ACE inhibitors are by far the largest and most investigated group, as it is 
evidenced by the number of papers published on this topic that are cited in the most 
comprehensive on-line databases, such as BIOPEP [7] (a general database of bioactive 
peptides, http://www.uwm.edu.pl/biochemia/index.php/pl/biopep), AHTPDB [8] (a 
specific database of antihypertensive peptides, http://crdd.osdd.net/raghava/ahtpdb/) or 
MBPDB [9] (a specific database of bioactive peptides in milk, 
http://mbpdb.nws.oregonstate.edu/). ACE participates in blood pressure regulation and 
inhibition of this enzyme, which has been demonstrated in most cases in vitro, could 
have an antihypertensive effect in vivo [2,8]. With this idea in mind, over the past years, 
several antihypertensive functional foods and nutraceuticals have been launched 
worldwide [2,10]. Consumer awareness about the benefits of these state-of-the-art 
pharmaco-nutritional products with bioactive peptides is continuously increasing, but 
also the concerns about the absence of reliable clinical trials supporting evidence for 
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health claims in vivo, allergenicity, cytotoxicity and stability of the peptides during 
gastrointestinal digestion [2]. Furthermore, it is necessary to develop novel analytical 
methods for the characterization of functional foods and nutraceuticals with bioactive 
peptides, as part of quality control, food safety and fraud control programs [11,12].  
 
Most of the methods that have been developed for the analysis of peptides in milk 
protein hydrolysates in a wide variety of food products are based on reversed-phase 
liquid chromatography-mass spectrometry (LC-MS) [10–12]. Capillary electrophoresis-
mass spectrometry (CE-MS) has been applied to a lower extent [11–15], despite the 
many and well-known benefits of this high-performance separation technique based on 
electromigration, which provides complementary, and very often better, separations 
than hydrophobicity-driven reversed-phase LC-MS, especially for charged polar 
compounds [16]. In this respect, we have described a CE-MS method to identify the 
presence of bioactive peptides in several commercial hypoallergenic infant formulas 
manufactured by hydrolysis of bovine milk proteins to diminish the risk of protein 
allergy [13,14]. A sample clean-up and preconcentration using a citrate buffer with 
dithiothreitol (DTT) and urea followed by solid-phase extraction (SPE) with a C18 
sorbent was applied before CE-MS. Then, features and bioactive peptides were searched 
in the electropherograms using the typical tools of the commercial software packages 
provided with the mass spectrometer [13,14] or similar alternatives freely available on-
line [15], which very often are difficult and tedious to use and must be carefully applied 
to avoid biased and unreliable results. As an alternative to this traditional data analysis 
methods, here, using as a case study a topic of interest nowadays in food analysis, such 
as the identification of antihypertensive peptides in a nutraceutical derived from a milk 
protein hydrolysate, we propose a data analysis workflow for data pre-processing, data 
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resolution and untargeted compound (feature) finding based on advanced chemometric 
tools [17], specifically regions of interest (ROIs) compression [18] and multivariate 
curve resolution alternating least squares (MCR-ALS) [19,20]. The core of the current 
data analysis workflow was adapted to be applied for the first time in foodomics from 
our previous LC-MS and CE-MS studies in metabolomics [21–23], because bioactive 
peptides are, as metabolites, low molecular mass compounds. For the identification of 
the selected features, we propose the use of the information available in the most 
comprehensive and currently updated on-line databases that were indicated above [7–9], 
which in case of AHTPDB [8] and MBPDB [9] were recently developed. The proposed 
analytical approach demonstrated a great potential for the simple, rapid and systematic 
identification of antihypertensive peptides in the nutraceutical sample. The obtained 
characteristic and activity-related fingerprint of antihypertensive bovine casein peptide 
fragments for the nutraceutical analyzed in this study could be very useful for quality 
control and authentication. 
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2. Materials and methods 
2.1. Chemicals, reagents and samples 
 
All the chemicals used in the preparation of background electrolytes (BGEs) and 
solutions were of analytical reagent grade or better. Acetic acid (HAc, glacial), formic 
acid (HFor, 25% (v/v)), sodium hydroxide (≥99.0% (m/m)) and water (LC-MS grade) 
were purchased from Merck (Darmstadt, Germany). Propan-2-ol (LC-MS grade) was 
purchased from Scharlau (Barcelona, Spain).  
The antihypertensive nutraceutical (N) was purchased at a local parapharmacy. In 
accordance with the information provided by the manufacturer, it is a mixture of vegetal 
extracts with approximately 9 g of hydrolyzed casein proteins per 100 g of nutraceutical 
(i.e. 62.5 mg / 1 tablet). The tablets were stored at room temperature when not in use. 
 
2.2. Electrolyte solutions, sheath liquid and sample solutions 
 
The BGE contained 1 M HAc (measured pH was 2.3) and was passed through a 0.22 
µm nylon filter (MSI, Westboro, MA, USA) before analysis. The sheath liquid solution 
consisted of a mixture of 60:40 v/v propan-2-ol:water with a 0.05% (v/v) of HFor. The 
sheath liquid was degassed for 10 min by sonication before use [13,14].  
 
Ten nutraceutical tablets were ground together with mortar and pestle until a fine 
powder was obtained. The powder (0.15 g) was added to a plastic vial with 1 mL of 
warm water (at 45ºC) and the mixture was shaken 1 h at 45ºC and 700 rpm [13,14,24]. 
Then, the mixture was centrifuged at 7000 x g for 10 min at 25ºC. The solid was 
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discarded and the supernatant was filtered through a 0.22 µm nylon filter before the 
analysis by CE-MS. Ten independent samples were weighed and prepared from the 
powdered tablets.  
 
2.3. Apparatus and procedures 
 
pH measurements were made with a Crison 2002 potentiometer and a Crison electrode 
52-03 (Crison Instruments, Barcelona, Spain). Centrifugal filtration was carried out in a 
cooled Rotanta 460 centrifuge (Hettich Zentrifugen, Tuttlingen, Germany). Agitation 
during sample extraction was performed with a Thermo-Shaker TS-100 (Biosan, 
Warren, USA). 
 
2.3.1 Capillary electrophoresis-mass spectrometry (CE-MS) 
 
CE-MS experiments were performed in a 7100 CE system coupled with an orthogonal 
G1603A sheath-flow interface to a 6220 oa-TOF LC/MS spectrometer (Agilent 
Technologies, Waldbronn, Germany). The sheath liquid was delivered at a flow rate of 
3.3 µL·min-1 by a KD Scientific 100 series infusion pump (Holliston, MA, USA). CE-
MS control and data acquisition were performed using ChemStation and MassHunter 
softwares (Agilent Technologies) [13,14]. 
 
A 72 cm total length (LT) x 75µm id x 360 µm od bare fused-silica capillary supplied by 
Polymicro Technologies (Phoenix, AZ, USA) was used for the separations. All capillary 
rinses were performed at high pressure (930 mbar). New capillaries were flushed with 1 
M NaOH (15 min), water (15 min) and BGE (30 min). The system was finally 
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equilibrated by applying the separation voltage (10 kV) for 15 min. Between workdays, 
the capillary was conditioned by rising successively with 0.1 M NaOH (5 min), water 
(10 min) and BGE (15 min). Both activation and conditioning procedures were 
performed off-line in order to avoid the unnecessary entrance of NaOH into the MS 
system. Samples were hydrodynamically injected at 34 mbar for 15 s. A separation 
voltage of 10 kV (normal polarity, anode at the injection capillary end) was applied for 
the electrophoretic separations at 25ºC. Between runs, the capillary was rinsed for 2 min 
with water and 2 min with BGE. The working BGE was refreshed after every analysis 
to ensure optimum separation repeatability.  
 
The accurate mass and high resolution TOF mass spectrometer was tuned and calibrated 
following the manufacturer’s instructions. The TOF mass spectrometer parameters in 
positive mode were optimized for the analysis of low molecular mass peptides: capillary 
voltage 4000 V, drying gas (N2) temperature 200ºC, drying gas flow rate 4 L·min
-1, 
nebulizer gas (N2) 7 psig, fragmentor voltage 215 V, skimmer voltage 60 V, OCT 1 RF 
Vpp voltage 300 V. Data were collected in profile at 1 spectrum/s between 200 and 
1500 m/z with the mass range set to high resolution mode (4 GHz). In order to ensure 
the accuracy of the molecular mass measurements, a standard solution of neuropeptides 
was analyzed, as quality control, after analyzing the nutraceutical samples [25]. 
 
2.3.2 Capillary electrophoresis-tandem mass spectrometry (CE-MS/MS) 
CE-MS/MS experiments were performed with the same CE instrument and sheath-flow 
interface coupled to an MSD ion trap (IT) mass spectrometer (Agilent Technologies). 
CE/MSD Trap Software (Agilent Technologies) was used for instrument control, data 
acquisition and data processing. The separation, sheath liquid, capillary voltage, drying 
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and nebulizer gas conditions were as in CE-MS. The rest of parameters of the IT mass 
spectrometers were optimized for the analysis of low molecular mass peptides: voltages 
on the capillary exit and skimmer were 150 and 50 V, respectively; octopole voltages 
were 15.41 and 3.34 V and the octopole radiofrequency was 267.2 Vpp; lens voltages 
were -11.32 and -100 V and the trap drive value was 70.4 (arbitrary units). MS/MS 
analyses were performed on the selected precursor ions (Table S-1) in the scanning 
range from 80 to 1250 m/z with an intensity threshold of 8000 and an MS/MS 
fragmentation amplitude of 1.0 V or 2 V (auto MS/MS mode).  
 
2.4. Data analysis 
 
This section and Figure 1 describe the dataset and data analysis workflow followed for 
data pre-processing, data resolution, feature finding, identification and confirmation of 
antihypertensive peptides in the nutraceutical sample, which is based on our previous 
studies in metabolomics [21–23].  
 
2.4.1. Data pre-processing  
 
First, CE-MS raw data from the nutraceutical samples were converted to mzXML 
format with the ProteoWizard software 3.0 (Palo Alto, CA, USA, freely available at 
http://proteowizard.sourceforge.net) and, then, imported into the MATLAB 
environment (MATLAB R2013a, The Mathworks Inc. Natick, MA, USA). The input 
full resolution data matrix was compressed through a “regions of interest” (ROI) search 
(Fig. 1A) using a home-made MATLAB program (A download link can be found in 
reference [18] o it is available upon request) [17,18,23]. Using this compression, ROI 
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values are searched among every migration time of the considered electrophoretic runs. 
These vectors with the common ROIs among the different migration times are grouped 
into a matrix and the final m/z values of each ROI are calculated as the mean of the m/z 
values obtained for that specific ROI. The number of rows and columns in the resulting 
matrix are equal to the total number of migration times of the considered run and to the 
total number of detected ROIs, respectively. 
 
ROI approach requires the input of several parameters, including the signal-to-noise 
threshold, the mass accuracy (i.e. m/z error) and the minimum number of migration 
times to be considered as a peak for each ROI. In our case, after visual inspection of the 
raw data and different preliminary tests, these parameters were set at 10,000 of MS 
intensity threshold signal, 0.05 m/z of mass accuracy and a minimum number of 25 
times in a peak to avoid losing information about low abundant compounds. After ROI 
compression a considerable size reduction was achieved and only the regions of the raw 
data with significant information about sample composition were considered for further 
analysis.  
 
In this case, run-to-run and sample-to-sample intensity reproducibilities were high 
because different extracts of the same nutraceutical were analyzed. Therefore, it was not 
necessary to normalize the intensity scale of the MS-ROI data matrices using internal 
standards. Intensity scale normalization is necessary after MS-ROI compression to 
correct among run instrumental intensity drifts, differences on sample matrix or any 
other fonts of low detection reproducibility [17,18,23]. Individual MS-ROI matrices 
were arranged in a column-wise augmented data matrix to find, by a pairwise search, 
common and uncommon ROI values among them. This search transformed the original 
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individual MS-ROI in data matrices with an equal number of m/z values (column of the 
final data matrix). The dimension of the ROI augmented data matrix (Daug, Fig. 1A) was 
the total number of migration times considered in the whole set of samples (rows) and 
the total number of considered m/z ROI values (columns). The augmented data matrix 
was considered for MCR-ALS analysis (Fig. 1B). 
 
2.4.2. MCR-ALS analysis 
 
MCR-ALS (MCR-ALS 2.0 MATLAB toolbox, freely available at 
http://www.mcrals.info [20]) was applied to resolve the component profiles from the 
nutraceutical samples.  MCR-ALS resolves as different components the overlapped 
electrophoretic peaks from the data and provides their electrophoretic profiles and mass 
spectra. This approach allows overcoming problems such as retention time shifts, 
background noise contributions, and differences in S/N among the different samples. 
 
MCR-ALS analysis of a data matrix D, following a bilinear model, gives the two factor 
matrices, C and ST, as in Eq. 1:  
𝐃 =  𝐂𝐒𝐓  + 𝐄               (1)         
 
where matrix C contains the electrophoretic profiles of the resolved contributions 
(components), matrix ST contains the corresponding mass spectra of the resolved 
contributions, and matrix E contains the residuals unexplained by the model.  
 
In this study, the different samples were simultaneously analyzed and compared by 
















]  =  𝐂𝐚𝐮𝐠𝐒
𝐓 +  𝐄𝐚𝐮𝐠    (2) 
 
This strategy allowed obtaining a common matrix of the mass spectra of the resolved 
components (ST) for all samples (ten components were selected in this study), and an 
augmented matrix describing the resolved electrophoretic profiles (Caug) in every 
sample. These electrophoretic peaks resolved in matrix Caug were allowed to vary in 
position (shifts) and shape among samples because the only requirement for a proper 
resolution is that the resolved mass spectra are the same for the common constituents in 
the different samples. This aspect is especially useful in the case of CE data where 
migration shifts among samples often occur and, hence, the alignment of electrophoretic 
peaks before analysis is not necessary [17,23]. 
 
MCR-ALS analysis was carried out following standard procedures for the determination 
of the number of components (SVD) and initial estimates (pure variable detection 
method based on the SIMPLISMA algorithm) [19,20]. ALS optimization was 
performed under non-negativity constraints for electrophoretic (Caug) and spectral (ST) 
profiles, and spectral normalization (equal height). All these tasks are incorporated in 
the MCR-ALS toolbox. 
 
2.4.3. Detection, identification and confirmation of antihypertensive peptides 
 
The mass spectra of the different MCR-ALS components contained in ST were searched 
for relevant compounds (features) (Fig. 1C). The mMass software 
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(http://www.mmass.org/ [26]), which is an open-source mass spectrometry software, 
was used to automate feature selection and database search. Once imported the mass 
spectra of the different components to the mMass environment, only the ions with an 
intensity higher than 5% of the maximum intensity were considered as significant 
features for database search. This intensity threshold was low enough and close to the 
mass spectra background to ensure detection of the most relevant features in the mass 
spectra of the resolved MCR-ALS components. 
 
An mMass database of antihypertensive peptides from milk proteins was built (see 
supplementary material for details) from the information collected after a “source 
search” with the keywords “milk” or “casein” in the on-line antihypertensive peptide 
database AHTPDB (http://crdd.osdd.net/raghava/ahtpdb/ [8]). The accurate 
experimental m/z value (m/zROI-MCR-ALS) of the significant features was searched in the 
lab-made mMmass database, considering different [M+zH]z+ ions, with z from +1 to +3. 
An error of 100 ppm from the m/ztheoretical values was used to evaluate the accuracy of 
the identifications (Er≤100 ppm, │m/zROI-MCR-ALS – m/ztheoretical │ / m/ztheoretical * 10
6). The 
tentative identifications were verified from the analysis of the raw mass spectra and 
extracted ion electropherograms (EIE) of the antihypertensive peptides, which were 
obtained with the MassHunter software, taking as a reference the m/z value and the 
migration time of the MCR-ALS resolved components. BIOPEP [7] and MBPDB [9] 
databases were also used to validate and complement the information provided by 
AHTPDB [8] for the identified antihypertensive peptides.  
 
The tentatively identified antihypertensive peptides were reliably confirmed by CE-
MS/MS comparing the experimental m/z of the product ions observed in the tandem 
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mass spectra with the theoretical m/z of the peptide fragments generated by mMass 
following Biemann’s nomenclature. Only the ions in the tandem mass spectra with an 
intensity higher than 5% of the maximum intensity were considered. 
 
3. Results and discussion 
 
3.1. CE-MS  
 
In a previous study we used CE-MS in positive ESI mode for separation and 
identification of bioactive peptides in hypoallergenic infant milk formulas derived from 
bovine milk protein hydrolysates [13,14]. Sample clean-up and preconcentration using a 
citrate buffer with dithiothreitol (DTT) and urea followed by SPE with a C18 sorbent 
was applied before CE-MS. In CE-MS, an acidic BGE (1 M HAc (pH 2.3)) and sheath 
liquid hydroorganic solution (60:40 (v/v) propan-2-ol:water with 0.05% (v/v) of HFor) 
resulted in excellent separation and detection of many low molecular mass bioactive 
peptides. These CE-MS conditions were used here for the analysis of the nutraceutical 
extracts, which contained approximately 9% (m/m) of hydrolyzed CSN proteins. The 
nutraceutical sample was simply prepared using hot water (45ºC/1h) as extractant 
[13,14,24], because we wanted to minimize the sample pretreatment. Furthermore, the 
nutraceutical extract, after centrifugation and filtration, was a transparent solution that 
could be directly analyzed by CE-MS without further clean-up, in contrast to the milk-
like emulsions obtained after adding hot water to the hypoallergenic infant milk 
formulas [13,14]. Fig. 2A shows the typical total ion electropherogram (TIE) by CE-MS 
for the nutraceutical extract. As can be observed, the nutraceutical extract presented a 
characteristic and complex electrophoretic profile with multiple compounds comigrating 
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between 7 and 20 min in several electrophoretic peaks of different intensities. To 
facilitate, speed-up and systematize data analysis, it was applied a workflow (Fig. 1) 
based on advanced chemometric tools that includes data pre-processing, resolution, 
feature finding and identification of antihypertensive peptides. 
 
3.2. Data analysis  
 
The data analysis workflow was applied to the dataset generated from the raw CE-MS 
electropherograms obtained for the analysis of the different independent nutraceutical 
extracts. The ROI search resulted in a great reduction of the m/z dimension (columns) of 
the input full resolution data matrix, from 171798 m/z values (raw CE-MS data, Fig. 
1A) until 954 m/z ROIs (CE-MS-ROI compressed data, Fig. 1A). The comparison of 
Fig. 2A and 2B shows a good agreement between the raw TIE and the detected ROIs for 
a typical nutraceutical extract (sample 1), suggesting the reliability of the compression. 
The ROI compression is a very efficient untargeted m/z peaking algorithm based on 
detection of relevant electrophoretic peaks above a certain intensity threshold. In 
contrast to the binning compression method, it does not arbitrarily skew m/z accuracy 
[17]. ROI compression greatly decreases the memory and computing requirements 
needed later for resolution by MCR-ALS with such complex data sets. 
 
MCR-ALS was applied to the column-wise augmented data matrix containing 
simultaneously the ROI-compressed data matrices of all the nutraceutical extracts. 
MCR-ALS resolved the electropherogram profiles and mass spectra of the common 
nutraceutical components in the different extracts (Fig. 1B). Ten components allowed 
explaining a high percentage of variance (R2=94.8%), with an acceptable lack-of-fit 
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value (LOF=22.9%). These figures of merits did not substantially improve if the 
number of components was increased, for example, until 25 (R2=97.6% and 
LOF=15.3%), and ten components were selected to avoid fitting non-systematic or 
residual data variance. Fig. 3 shows the typical electrophoretic profiles of the 10 
resolved components for the nutraceutical extract (sample 1), which agreed to a large 
extent with the most relevant 954 m/z ROIs detected after data compression (Fig. 2B). 
Table 1 shows the average relative area of the different components (%Area) calculated 
from the values obtained for the electrophoretic profiles of the different extracts. This 
area gives a rough idea of the total concentration of the compounds in the MCR-ALS 
resolved components, but being aware that the relation between the MS signal and the 
concentration may vary notably between the different compounds, even between those 
from the same structural family (e.g. peptides). The mass spectra of the components 
were screened for relevant features. Only the mass spectra ions with a relative intensity 
(%Intensity) higher than 5% of the maximum intensity were considered as significant 
features for the targeted database mass search. The mMass MS software was used in the 
last part of the data analysis workflow because it allowed processing, as line mass 
spectra, the mass spectra of the components directly exporting from MATLAB in text 
format [26]. Furthermore, mMass had many other interesting features for this study 
related to peptide sequence editing, molecular formula generation, accurate molecular 
mass and m/z calculation, database building and search.  
 
Table 1 shows the 22 antihypertensive peptides tentatively identified in the nutraceutical 
extract after database search and comparison of the raw EIE and mass spectra with the 
corresponding MCR-ALS component profiles and mass spectra. Fig. 4 shows as an 
example this confirmatory comparison for some of the peptides. As can be observed, the 
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agreement between the raw EIE (Fig. 4A) and the MCR-ALS components (Fig. 4B) was 
good. Regarding the zoomed regions of the mass spectra shown as insets, the MCR-
ALS mass spectra showed a smaller number of ions in some of the cases because the 
comigrating compounds were resolved in different components (e.g. compare Fig. 4A-ii 
and B-ii). As can be observed in Table 1, as the nutraceutical was prepared from 
hydrolyzed casein proteins (9% (m/m)), all the identified antihypertensive peptides 
corresponded to bovine CSN fragments, from 2 to 15 amino acids. Furthermore, in 
general, they were found at low concentration, as can be observed by the %Area of the 
different components and the %Intensity of the detected ions. The half maximal 
inhibitory concentration (IC50) for angiotensin-converting enzyme (ACE) was reported 
for some of the peptides, and ranged from 1.7 µM for the most bioactive peptide 
(SKVYPFPGPI) until 2439 µM for the least (RL). In addition to the antihypertensive 
activity, some peptides were also reported to be dipeptidyl peptidase IV inhibitors (DPP 
IV inhibitor), and hence relevant for diabetes mellitus type 2 treatment, and another 
DPP IV inhibitor, antioxidative, renin inhibitor, calmodulin-dependent cyclic nucleotide 
phosphodiesterase (CaMPDE) inhibitor. All the antihypertensive peptides were reported 
in AHTPDB database [8], which in our opinion is the most comprehensive 
antihypertensive peptide database of the three investigated in this study. Anyway, it is 
always recommended crosschecking the information for the identified peptides in 
AHTPDB database with BIOPEP [7] and MBPDB [9] databases, as well as with the 
original references cited in the databases. Furthermore, it is necessary to use a 
specialized MS software such as mMass to ensure accurate molecular mass and m/z 




Regarding the accuracy of the identifications, an error (Er) of 100 ppm from the 
m/ztheoretical values was considered. This value was a good compromise to avoid the loss 
of potential identifications, because Er was measured on the mass spectra of the 
different MCR-ALS components, which were resolved considering all the nutraceutical 
extracts. As can be observed, the mass spectra shown as insets in Fig. 4A-i-iii and B-i-
iii show some differences in the m/z values of the ions between the experimental and the 
MCR-ALS mass spectra.  
 
In order to reliably confirm the identity of the peptide candidates, targeted CE-MS/MS 
experiments were performed. Table S-1 shows the selected precursor ions and the 
detected product ions for the tentatively identified antihypertensive peptides of Table 1. 
The identity of 17 antihypertensive peptides was confirmed (highlighted in bold in 
Table 1 and Table S-1) from the tandem mass spectra fragmentation patterns. As an 
example, Fig. S-1 shows the EIE, the mass spectrum, the tandem mass spectrum and the 
peptide fragments obtained for the antihypertensive peptide DKIHPF (m/ztheoretical = 
378.7056, z=+2). The identity of 5 peptides could not be confirmed by CE-MS/MS 
(Table 1 and Table S-1). VLNENL, IP/LP and PL peptides were not detected due to the  
lower sensitivity of the IT mass spectrometer when compared to the TOF mass 
spectrometer. Only the identity of the ENLLRF peptide could not be confirmed because 
the product ions in the MS/MS spectra did not match with the expected fragmentation 
pattern. This low false identification rate suggested the validity of the accurate mass and 
high resolution TOF mass spectrometer for the straightforward and inexpensive 
untargeted screening of antihypertensive peptides. The number of confirmed 
antihypertensive peptides was high, considering the low content of hydrolyzed casein 
proteins in the nutraceutical and the very simple sample pretreatment. In general, these 
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results suggest the great potential of the proposed analytical methodology for the 
simple, rapid and systematic analysis of bioactive peptides in nutraceuticals and milk 
derived functional foods, as part of quality control, food safety and fraud control 
programs. More broadly, it could be adapted to similar untargeted and targeted CE-MS 
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Figure 1. Data analysis workflow: (A) data pre-processing, (B) data resolution and (C) 




Figure 2. (A) Experimental total ion electropherogram (TIE) and (B) detected regions 
of interest (ROI) for the nutraceutical extract sample 1 (each colour trace stands for a 
ROI with a different m/z value in sample 1. No colour legend is shown because of the 






Figure 3. Resolved components by multivariate curve resolution alternating least 
squares (MCR-ALS) for the nutraceutical extract sample 1 (each colour trace stands for 





Figure 4. (A) Experimental extracted ion electropherogram (EIE) and (B) 
corresponding multivariate curve resolution alternating least squares (MCR-ALS) 
resolved component for the nutraceutical extract sample 1. The tentatively identified 
antihypertensive peptides are i) DKIHPF (m/ztheoretical = 378.7056, z=+2), ii) 




Table 1. Antihypertensive peptides tentatively identified in the mass spectra of the resolved MCR-ALS components of the nutraceutical extract 
after database search. All peptides were confirmed by comparison of the experimental CE-MS with the MCR-ALS data (CSN=casein). 
MCR-ALS component Antihypertensive peptidesa 
Number 
%Area  






Er (m/z) Er (ppm)  z  
%Intensity (in the 
spectra of the MCR-
ALS components) 






1 32.5 203.1408 203.1390 0.0018 8.8 1 22 IA kappa-CSN 153c (soybean) AHTPDB and BIOPEP 
2 13.5 378.7373 378.7056 0.0317 84 2 100 DKIHPF beta-CSN 257 




396.2342 396.2241 0.0101 25 2 8.3 ENLLRF alpha-CSN  
82  
(caprine milk) 
AHTPDB and MBPDB 
796.4355 796.4240 0.0115 14 1 7.0 YIPIQY kappa-CSN  
10 
(ovine milk) 
AHTPDB, BIOPEP and 
MBPDB 

4 2.5 701.4156 701.3828 0.0328 47 1 33 VLNENL alpha-CSN - AHTPDB 
5 3.4 552.8019 552.8080 -0.0062 -11 2 18 SKVYPFPGPI 
beta-CSN (sequence conflict 
SLVYPFPGPI)b 
1.7 AHTPDB and BIOPEP 
6 12.2 - - - - -  - - - - -
7 2.0 
276.1533 276.1554 -0.0021 -7.7 1 10 
EK alpha-CSN, beta-CSN and kappa-CSN -c 
AHTPDB and BIOPEP 

KE alpha-CSN and beta-CSN - 
288.2096 288.2030 0.0066 23 1 29 
IR kappa-CSN 695e 
AHTPDB and BIOPEP 

RL alpha-CSN 2439 




AHTPDB and BIOPEP 

RF kappa-CSN 93 (sake lees) 
530.8057 530.7615 0.0442 83 2 22 IASGEPTSTPT kappa-CSN  - AHTPDB 
580.0036 579.9734 0.0302 52 3 8.9 KYPVQPFTESQSLTL beta-CSN 44 AHTPDB 
8 1.8 
229.1541 229.1547 -0.0006 -3.0 1 13 
IP / LPd alpha-CSN, beta-CSN and kappa-CSN 130c / -c 
AHTPDB, BIOPEP and 
MBPDB 

PLd alpha-CSN and beta-CSN -c 
246.1622 246.1561 0.0061 25 1 37 AR kappa-CSN 95.5 AHTPDB and BIOPEP 
318.1715 318.1812 -0.0097 -30 1 8.8 LW  alpha-CSN 15f 
AHTPDB, BIOPEP and 
MBPDB 

335.1816 335.2148 -0.0332 -99 3 12 LKKYKVPQ alpha-CSN - AHTPDB 
342.2635 342.2387 0.0247 72 1 14 IPI kappa-CSN - AHTPDB 
867.451 867.5298 -0.0788 -91 1 11 SKVLPVPQ beta-CSN 39 AHTPDB and MBPDB 
9 4.0 361.1607 361.1870 -0.0264 -73 1 58 GVW alpha-CSN (sequence conflict GAW)b 240 AHTPDB and BIOPEP 
10 21.9 - - - - - - - - - - -
29 
 
a)All the peptides are bovine CSN fragments. Most of them were reported after enzymatic hydrolysis of milk, dairy products and purified CSNs of bovine origin, excepting otherwise indicated. 
b)The peptide sequence from bovine CSN in the peptide databases differ from the most typical bovine CSN proteoform reported in Uniprot knowledgebase (www.uniprot.org). 
c)This peptide was also dipeptidyl peptidase IV inhibitor (DPP IV inhibitor).  
d)These peptides cannot be differenced from their MS/MS fragmentation patterns. 
e)This peptide was also antioxidative, renin inhibitor, calmodulin-dependent cyclic nucleotide phosphodiesterase (CaMPDE) inhibitor and DPP IV inhibitor. 
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Building the mMass database of antihypertensive peptides from milk proteins 
The mMass database of antihypertensive peptides from milk proteins was built from the 
information collected after a “source search” with the keywords “milk” or “casein” in 
the on-line antihypertensive peptide database AHTPDB 
(http://crdd.osdd.net/raghava/ahtpdb/ [8]). A tab-delimited text file with the AHTPDB 
database ID number, the source and the one letter code sequence of the antihypertensive 
peptides was saved in Microsoft Excel 2016, and converted to FASTA format using a 
freely available on-line application 
(http://sequenceconversion.bugaco.com/converter/biology/sequences/tab_to_fasta.php). 
The FASTA file was imported into mMass to generate the molecular formulas of the 
different peptide sequences, which later were used to calculate the accurate 
monoisotopic molecular mass and the accurate m/z values of differently charged 
molecular ions (m/ztheoretical). The Excel file with the AHTPDB database ID, the source 
and the sequence was completed with the molecular formulas obtained by mMass from 
the imported FASTA file. Then, the Excel file was given the appropriate XML format 
using as an XML origin one of the default databases available in mMass (e.g. 
compounds.xml). Finally the Excel file was exported as an XML file ready to use as a 










Table S-1. CE-MS/MS confirmation of the antihypertensive peptides identified in the 
mass spectra of the resolved MCR-ALS components of the nutraceutical extract after 
database search. 
a)These peptides cannot be differenced by their MS/MS fragmentation patterns. 
MCR-ALS Precursor ion Antihypertensive peptides Product ions 
Component m/zexperimental z m/ztheoretical Sequence m/zexperimental z Sequence 
1 203.1 1 203.1 IA - - - 
2 378.7 2 378.8 DKIHPF 
513.3 1 y4 
494.3 1 b4 
369.8 2 M-H2O 
321.2 2 y5 
263.2 1 y2 
3 
396.2 2 396.2 ENLLRF - - - 
796.4 1 796.4 YIPIQY 
779.9 1 M-NH3 
778.9 1 M-H2O 
615.7 1 b5 
374.5 1 b3 
4 701.4 1 701.4 VLNENL - - - 
5 552.8 2 552.8 SKVYPFPGPI 
501.2 2 z9 
473.3 2 a9 
437.1 2 z8 
387.4 2 z7 
312.1 1 x3 
216.1 1 b2 
6 - - - - - - - 
7 
276.2 1 276.2 
EK 258.2 1 M-H2O 
KE 258.2 1 M-H2O 
288.1 1 288.2 
IR 
271.2 1 M-NH3 
270.2 1 M-H2O 
175.1 1 y1 
RL 
271.2 1 M-NH3 
270.2 1 M-H2O 
157.1 1 b1 
322.3 1 322.2 
FR 
305.2 1 M-NH3 
304.2 1 M-H2O 
175.1 1 y1 
RF 
305.2 1 M-NH3 
304.2 1 M-H2O 
157.1 1 b1 
530.8 2 530.8 IASGEPTSTPT 
760.4 1 c8 
638.5 1 b7-H2O 
217.1 1 y2 
580.1 3 580.0 KYPVQPFTESQSLTL 
433.2 1 y4 
418.1 3 y11 
416.1 1 z4 
8 
229.2 1 229.2 
IP / LPa - - - 
PL - - - 
246.2 1 246.2 AR 
229.1 1 M-NH3 
228.1 1 M-H2O 
318.2 1 318.2 LW 
300.2 1 M-H2O 
205.1 1 y1 
188.1 1 z1 
8 
335.2 3 335.2 LKKYKVPQ 
 2 a5 
 3 a6 
 1 x1 
 1 y3 
342.2 1 342.2 IPI 
- 1 M-NH3 
 1 M-H2O 
867.5 1 867.5 SKVLPVPQ 
849.6 1 M-H2O 
641.4 1 c6 
9 361.2 1 361.2 GVW 
287.1 1 z2 
129.1 1 a2 





Figure S-1. (A) Experimental extracted ion electropherogram (EIE) and mass spectrum, 
(B) tandem mass spectrum and (C) peptide fragmentation obtained by CE-MS/MS for the 
































































A) Extracted ion electropherogram (EIE) (m/z=378.7, z=+2)
Mass spectrum
